High-risk and ultra-high-risk multiple myeloma, characterized by the presence of cytogenetic abnormalities and/or extramedullary disease, represent......READ MORE
The use of chimeric antigen receptor (CAR) T-cell therapy can achieve remarkable responses in heavily pretreated patients with multiple myeloma. Cy......READ MORE
High-risk smoldering multiple myeloma represents a subset of disease that is more likely to progress to active multiple myeloma. Efforts to refine ......READ MORE
Cytogenetic changes in multiple myeloma are among the most important prognostic factors, and treatments may have implications on the accumulation o......READ MORE
Continuous antimyeloma therapy has been shown to prolong disease control and has replaced the fixed-duration approaches of the past. Ideal properti......READ MORE
